HIV vaccines guide rare immune cells to produce broadly neutralizing antibodies, three Nature studies show
This digest was compiled by AI from multiple sources — links to the originals are below.
Three studies published in Nature this week demonstrate that experimental HIV vaccines can guide rare immune cells to produce broadly neutralizing antibodies, which can block a wide range of HIV strains. The findings validate a germline-targeting strategy that could eventually lead to an effective vaccine against the virus, researchers say.
Germline-Targeting Vaccines
The vaccines are designed to engage rare naive B cells that possess the genetic potential to produce broadly neutralizing antibodies against HIV. By using precisely engineered mimics of the virus's envelope protein, they activate these precursor cells and guide them through antibody maturation. Teams led by William Schief at Scripps Research and Rogier Sanders at the University of Amsterdam demonstrated this in animal studies using mice and macaques. The approach relies on decades of structural biology research mapping vulnerable sites on HIV's spike protein.
Proof in Animal Models
In two independent studies, the vaccines successfully stimulated rare B cells and induced broadly neutralizing antibodies effective against a diverse panel of HIV-1 strains in laboratory assays. A third led by Bette Korber at Los Alamos National Laboratory confirmed that the vaccines targeted the correct precursor cells, analyzing the genetic pathways of the immune responses. These results are the first to show that a vaccine can elicit bnAbs in animals with complex immune systems. The antibodies neutralized over 70% of HIV strains tested, offering a promising benchmark for future human trials.
Human Trials Ahead
Earlier human trials have shown that germline-targeting vaccines can prime the right B cells, but until now they had not produced bnAbs in humans. The new animal data bolster confidence that refined vaccine versions could achieve that goal. Optimizing dosing schedules and demonstrating protection against infection remain key challenges. Several research groups are now planning larger studies in nonhuman primates to test durability and efficacy before seeking regulatory approval for human trials.
What's Next
The first human clinical trials of the refined vaccines are expected to begin within two years, pending regulatory review. It remains unclear whether the broadly neutralizing antibody responses observed in animals will translate into effective protection against HIV infection in people.
1 source
HIV vaccines guide rare immune cells to produce broadly neutralizing antibodies, three Nature studies show
